Table 3 Evaluation of pre- and post-treatment ARRs in NMOSD-NOSIS and NMOSD-OSIS (serumpositive for AQP4)
Treatment | Therapy duration,y(range) | Patient groups(n) | Pre-treatment | Post-treatment | P value | Relapse-free within 1 year, n(%) | Relapse-free within 2 year, n(%) |
|---|---|---|---|---|---|---|---|
Azathioprine | 2.00(1.50–3.00) | NMOSD-NOSIS n = 17 | 2.00(0.50- 3.00) | 0.50(0–1.00) | 0.003 | 11/17(64.71) | 7/16(43.75) |
3.00(2.00–5.00) | NMOSD-OSIS n = 161 | 1.00(0.50–1.53) | 0.27(0–0.67) | < 0.001 | 103/160(64.38) | 70/138(50.72) | |
Mycophenolate mofetil | 2.00(2.00–4.00) | NMOSD-NOSIS n = 10 | 2.00(1.45–2.25) | 0.25(0–0.56) | 0.008 | 8/10(80.00) | 4/9(44.44) |
2.00(1.00–3.00) | NMOSD-OSIS n = 95 | 0.80(0.50–1.25) | 0(0–0.50) | < 0.001 | 77/95(81.05) | 38/75(50.67) | |
Rituximab | 1.00(1.00–1.00) | NMOSD-NOSIS n = 3 | 1.25(--) | 0(--) | 0.285 | 2/3(66.67) | -- |
2.00(1.00–2.50) | NMOSD-OSIS n = 17 | 1.00(0.71- 2.00) | 0.33(0–1.25) | 0.055 | 10/17(58.82) | 6/13(46.15) |